banner1y
banner2——愿景-恢复的
banner33

Company Profiel

2001

Established in Shanghai

The first

Category I Major Innovative Biologic Drug during the 11th Five-Year Plan period-PUK

17

First-in-class/best-in-class biological product portfolio

Leading

Perfusion culture technology platform for mammalian cells

Commercialization platforms which integrates

The research and development, manufacturing, and sales.

Field of Disease

Tasly Biopharma focuses on the development of biologic drugs in three major therapeutic areas of cardiovascular diseases, oncology and autoimmune diseases, and alimentary tract and metabolism, and has a preferred product portfolio of more than 19 biological assets capable of continuous development.

We have the new generation of fibrin-specific thrombolytic drug, PUK, available on the market and other products that are currently under development such as acute ischemic stroke (AIS) B1140, acute pulmonary embolism (APE) B1448 and PCSK9 monoclonal antibody B1655 for targeted treatment of hypercholesterolemia.

Tasly Biopharma focuses on the development of new drugs such as monoclonal antibodies, bispecific antibodies, oncolytic virus, and immunotherapeutic products, and the product varieties under development include a fully-human EGFR-targeted monoclonal antibody SY101 for the treatment of advanced colorectal cancer and oncolytic virus product T601 for the treatment of advanced malignant solid tumors.

In response to unfulfilled clinical needs in the field of alimentary tract and metabolism, Tasly Biopharma is developing products such as T101, a new immunotherapeutic vaccine for chronic hepatitis B, and B1344 for diabetes and NASH.

The new generation of fibrin-specific thrombolytic drugs

An integrated commercial platform that covers all life cycles of biological drugs

Complete marketing network

Open-access biologics R&D platform

The manufacturing capabilities that are based on the perfusion culture technology

Talent Recruitment

talent is the root that drives scientific and technological innovation

We will build a biopharmaceutical company that continues to innovate in key therapeutic areas. In the process, we will never stop looking for like-minded colleagues to fight and grow together.

News Center

Partner

About us

Company Profile
Chairman’s Message
Mission and Vision Management Team
Board of Directors
Contact Us

Product Center

Products
Pipeline
Clinical Recruitment
About PUK

R&D and Innovation

Field of Disease
R&D  Model
R&D  System
R&D  Team
Quality Systems
Foreign Cooperation

Commercialization Capabilities

Manufacturing Process Manufacturing Operations
Precision Marketing

News Center

Media Reports
Company News

Careers

Corporate Culture
Job Opportunities